Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.
Location: United States, California, Menlo Park
Employees: 11-50
Phone: +1 833-466-7284
Total raised: $18M
Founded date: 2014
Investors 3
| Date | Name | Website |
| 10.02.2021 | Genoa Vent... | genoavc.co... |
| - | ND CAPITAL | nd.capital |
| - | Vertical V... | vvp.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.09.2020 | Series B | $18M | - |
Mentions in press and media 4
| Date | Title | Description |
| 26.08.2021 | Ionpath Expands Biopharmaceutical Partnerships Program to Rapidly Deliver Novel Insights Utilizing the Company's High-Definition Spatial Proteomics Platform | |
| 28.09.2020 | IONpath Raises $18M in Series B Financing | IONpath, Inc., a Menlo Park, Calif.-based developer of high-definition spatial proteomics, closed a $18m Series B financing. The round was led by Samsara BioCapital, with participation from new investor Bruker Corporation, and existing majo... |
| 24.09.2020 | IONpath Closes $18 Million Series B Financing to Advance Precision Medicine | Proceeds will be used for the further development and deployment of IONpath’s revolutionary MIBI technology, affirming its leadership in high-definition spatial proteomics NEWS PROVIDED BY IONpath, Inc. Sep 24, 2020, 08:00 ET MENLO PARK,... |
| 24.09.2020 | IONpath Closes $18 Million Series B Financing to Advance Precision Medicine |